Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Maher Albitar, Sally Agersborg, Hong Zhang, Adam Albitar, Ahmad Charifa, Andrew Pecora, David Siegel, Andre Goy, Jamie Koprivnikar, James McCloskey, Katherine Linder

Blood (2025) 146 (Supplement 1): 5611.

https://doi.org/10.1182/blood-2025-5611

Published: 2025

Journal Articles

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7386.

https://doi.org/10.1182/blood-2025-7386

Published: 2025

Journal Articles

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Maher Albitar, Hong Zhang, Gustavo Rivero, David Swoboda, Sally Agersborg, Adam Albitar, Ahmad Charifa, Andrew Ip, Andre Goy, Andrew Pecora, David Siegel, Kelly West Fitzpatrick, Katherine Linder, Jamie Koprivnikar, James McCloskey

Blood (2025) 146 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2025-5251

Published: 2025

Journal Articles

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

Sarvarinder Gill, Maher Albitar, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2025-1731

Published: 2025

Journal Articles

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7032.

https://doi.org/10.1182/blood-2025-7032

Published: 2025

Journal Articles

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Blood (2025) 146 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2025-3471

Published: 2025

Journal Articles

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Sarvarinder Kaur Gill, Geeny Lee, Joelle Rubin, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, James McCloskey

Blood (2024) 144 (Supplement 1): 1448.

https://doi.org/10.1182/blood-2024-210149

Published: 2024

Journal Articles

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Maher Albitar, Sally Agersborg, Ahmad Charifa, Hong Zhang, Andrew Ip, Katherine Linder, Andrew L Pecora, Jamie Koprivnikar, Andre Goy, James McCloskey

Blood (2024) 144 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2024-203870

Published: 2024

Journal Articles

Decades of Improvement in Cardiovascular Morbidity and Mortality in Leukemia Patients Reversed in 2020: Covid? Novel Agents? Neither?

Tony Varughese, Eli Zolotov, Maciej Kabat, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2023-188331

Published: 2023

Journal Articles

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Jessica K. Altman, Yasmin Abaza, Michael Keng, Abhishek Maiti, Jamie Koprivnikar, Shoshi Tessler, Chen Blumberg, Liat Flaishon, Ruth Ben Yakar

Blood (2023) 142 (Supplement 1): 5970.

https://doi.org/10.1182/blood-2023-185694

Published: 2023

Journal Articles

No Improvement in the Age Adjusted Mortality of Older Adults with Acute Lymphoblastic Leukemia Despite the Availability of Blinatumumab, Inotuzumab and Novel TKIs : A 1999-2020 Analysis in the United States

Tony Varughese, Maciej Kabat, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 1465.

https://doi.org/10.1182/blood-2023-188366

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

COVID-19 Related Mortality Does Not Correlate with Vaccine Availability in Leukemia Patients: 2020-2023 Analysis in the United States

Tony Varughese, Maciej Kabat, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2023-182557

Published: 2023

Journal Articles

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2023-187606

Published: 2023

Journal Articles

Unveiling Alarming Trends: Worsening All Cause Mortality in US Adults over 25 with Amyloid 1999-2020 Analysis

Maciej Kabat, Tony Varughese, Eli Zolotov, Jamie Koprivnikar

Blood (2023) 142 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2023-188372

Published: 2023

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Maher Albitar, Andrew Ip, Andre H. Goy, Katherine Linder, Jeffrey Justin Estella, Ahmad Charifa, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James McCloskey

Blood (2022) 140 (Supplement 1): 6270–6271.

https://doi.org/10.1182/blood-2022-167406

Published: 2022

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Maher Albitar, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James K McCloskey

Blood (2021) 138 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2021-148164

Published: 2021

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Decades of Improvement in Cardiovascular Morbidity and Mortality in Leukemia Patients Reversed in 2020: Covid? Novel Agents? Neither?

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

No Improvement in the Age Adjusted Mortality of Older Adults with Acute Lymphoblastic Leukemia Despite the Availability of Blinatumumab, Inotuzumab and Novel TKIs : A 1999-2020 Analysis in the United States

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

COVID-19 Related Mortality Does Not Correlate with Vaccine Availability in Leukemia Patients: 2020-2023 Analysis in the United States

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Unveiling Alarming Trends: Worsening All Cause Mortality in US Adults over 25 with Amyloid 1999-2020 Analysis

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only